208 results on '"Cardenal, Felipe"'
Search Results
2. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
3. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
4. Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer
5. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database
6. Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer
7. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
8. Supplementary Table 1 from Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer
9. Supplementary Data from Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
10. Supplementary Figure S5 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
11. Supplementary Tables S1-S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
12. Cognitive and Brain Structural Changes in a Lung Cancer Population
13. KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
14. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
15. Brain damage following prophylactic cranial irradiation in lung cancer survivors
16. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study
17. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer
18. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
19. Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
20. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
21. Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation Chemotherapy
22. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
23. Screening for epidermal growth factor receptor mutations in lung cancer
24. PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations
25. A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours
26. Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer
27. Predictive biomarkers in the management of EGFR mutant lung cancer
28. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer
29. Radiotherapy and concurrent weekly docetaxel following cisplatin-docetaxel induction chemotherapy in unresectable Stage IIIA-B non-small-cell lung cancer: A randomised phase II trial
30. Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial
31. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer
32. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer
33. Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy.
34. Meningeal carcinomatosis as a cause of partially reversible blindness
35. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
36. MA06.07 Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients
37. P2.02-010 Prognosis Impact of Oligoprogression Following Definitive Chemo-Radiotherapy in Stage III Non-Small Cell Lung Cancer
38. P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC
39. Treatment of resectable stage IIIA non-small cell lung cancer
40. P2.05-054 Radiation Pneumonitis; Early Diagnosis and Protein Expression Profile in NSCLC Patients
41. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
42. A prospective study assessing the value of geriatric assessment in elderly patients with stage III NSCLC for concurrent chemoradiation.
43. Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
44. Opioids for the Management of Dyspnea in Cancer Patients: Evidence of the Last 15 Years—A Systematic Review
45. Brain damage following prophylactic cranial irradiation in lung cancer survivors
46. BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).
47. Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
48. Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer
49. Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).
50. Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.